Jordan Johnson: Why Bridge Oncology is positioned the way it is
Jordan Johnson, Founding Partner of Bridge Oncology and Founder of The Healthcare Hub, shared a post on LinkedIn:
“Pay Attention.
This is why Bridge Oncology is positioned as we are!
The recent Senate confirmation hearing for Mehmet Oz as CMS Administrator put a spotlight on the growing role of AI in healthcare decision-making – particularly in Medicare Advantage (MA) prior authorizations. While AI has the potential to streamline processes, it also introduces significant risks if not properly regulated.
The issue isn’t just automation – it’s control. Without strict oversight, AI-driven coverage decisions could exacerbate the very inefficiencies and denials they’re supposed to fix. A growing string of lawsuits has already alleged that insurers are using AI to override clinical judgment, deny necessary care, and prioritize cost savings over patient outcomes.
Oz acknowledged that ‘prior authorization is a pox on the system’ and suggested that standardizing approval criteria could reduce unnecessary delays. But even with AI-driven efficiencies, a human must have the final say in these decisions – otherwise, we risk replacing individualized patient assessments with arbitrary algorithms.
As AI continues to reshape healthcare, tighter controls from the top down are essential. CMS must set clear guardrails to ensure that AI serves patients – not just payers.
If left unchecked, we risk turning a broken system into an even bigger crisis.”
More posts featuring Jordan Johnson.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023